Salarius Pharmaceuticals (SLRX) and Decoy Therapeutics announce the completion of their strategic merger with the combined company now focused on advancing Decoy’s pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. Prior to this merger, Decoy attracted financing from institutional investors as well as significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program, among other sources. Decoy also received QuickFire Challenge award funding provided by the Biomedical Advanced Research and Development Authority through BLUE KNIGHT, a legacy collaboration between Johnson & Johnson Innovation – JLABS and BARDA within the Administration for Strategic Preparedness and Response.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLRX:
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Why Is Salarius Pharmaceuticals Stock (SLRX) Up 65% Today?
- Salarius Pharmaceuticals announces pricing of $7M offering of stock, warrants
- Salarius Pharmaceuticals Approves CEO Bonus for Merger
- Salarius Pharmaceuticals Regains Nasdaq Compliance for Merger